Guardant Health Introduces Guardant Galaxytm Suite of Advanced AI Analytics to Enhance Its Portfolio of Cancer Tests and Accelerate Biomarker Discovery
Guardant Health, a leading precision oncology company, announced the introduction of Guardant GalaxyTM, a suite of advanced analytical technologies developed internally and through outside partnerships to enhance the performance and clinical utility of Guardant Health’s portfolio of cancer tests and to power the next generation of biomarker and drug discovery.
“Management’s Discussion and Analysis of Financial Condition and Results of Operation”
“Precision medicine has clearly demonstrated its potential to improve outcomes for patients with cancer, and our genomic profiling tests play a key role by identifying cancer biomarkers and other factors that can inform diagnosis and therapy selection,” said Helmy Eltoukhy, co-CEO of Guardant Health. “With Guardant Galaxy, we are now accessing the most advanced AI analytics and complementary technologies from leading companies in cancer diagnostics. This will enable us to enhance the capabilities of our tests to provide oncologists and researchers with precise and actionable information and accelerate the development of new biomarker and drug discovery technologies.”
Recommended AI News: OmniML Secures $10 Million to Accelerate AI Computing on Edge Devices
The first application in the Guardant Galaxy suite is an AI-backed digital pathology platform developed by Lunit, a Seoul, South Korea-based company that develops AI solutions for precision diagnostics and therapeutics. The AI-powered scoring algorithm for the enhanced Guardant360 TissueNext PD-L1 test, which is now commercially available,* improved detection of the cancer biomarker by more than 20 percent compared to manual pathologist interpretation in the most challenging non-small cell lung cancer (NSCLC) cases. Findings from a recently published study indicate that the algorithm can assist pathologists by minimizing interpretation discrepancy and allowing for much better prediction of treatment outcomes.1
“We are excited to partner with Guardant Health in leveraging the power of AI and digital pathology to enhance the capabilities of Guardant’s portfolio for cancer patients,” said Brandon Suh, CEO at Lunit. “The development of the AI-supported scoring algorithm for the Guardant360 TissueNext PD-L1 test is a great example of using advanced medical image analytics to enhance precision diagnostics in lung cancer and help oncologists find the right treatment for the right patients.”
Recommended AI News: Fastly Acquires Fanout to Unlock Real-Time App Development at the Edge
In addition to enhancing current standard-of-care biomarker interpretation, early Guardant Galaxy applications will also include novel native AI analysis applications, including the prediction of patient response to immunotherapy based on the spatial distribution of immune, stromal and tumor cells in standard H&E-stained slides.
Additional planned applications include enhanced oncology drug and biomarker discovery and development capabilities based on mining the extensive genomic and epigenomic data produced by Guardant Health’s diagnostic tests, cross-referenced to real-world outcomes data available through the GuardantINFORM data platform. Guardant Health also plans to expand the Guardant Galaxy technology suite over time to include other technology partnerships that will support additional segments of its cancer diagnostics portfolio.
Recommended AI News: CommScope Propels Data Centers into the Future
[To share your insights with us, please write to firstname.lastname@example.org]
Comments are closed.